One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Jan 1 1983|
All Science Journal Classification (ASJC) codes
- Cancer Research